ThirtyFiveBio Limited has received GBP 643,371 (~USD 817,000) in grant funding from Innovate UK. This is the company's second Biomedical Catalyst Grant within a year, bringing its total funds to GBP 1.1 million (~USD 1.4 million).
The funds will be used for preclinical research, enabling the company to adopt a precision medicine strategy for patient selection during the clinical development of its first-in-class GPR35 inhibitors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.